Similarly, in the cohort by Aytaç et al. [33], all patients with sJIA seen after 2011 received anakinra, while patients with SLE were treated more frequently with IVIG (68% vs 33%) and etoposide (50% vs 32%), and received IL-1 blockade in 30% of cases. This evidence concerns the gene IL1B and systemic-onset juvenile idiopathic arthritis.